Ipratropium Bromide Inhalation Solution, 0.02% Prescribing Information Rx Only RPIN0020 | Ipratropium Bromide [REMEDYREPACK INC.] | BioPortfolio

13:13 EST 27th January 2019 | BioPortfolio

Note: While we endeavour to keep our records up-to-date one should not rely on these details being accurate without first consulting a professional. Click here to read our full medical disclaimer.

Ipratropium Bromide Inhalation Solution, 0.02% Prescribing Information 

The active ingredient, ipratropium bromide monohydrate, USP, is an anticholinergic bronchodilator chemically described as 8-azoniabicyclo [3.2.1]- octane, 3-(3-hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-, bromide, monohydrate (endo, syn)-, ( +)-; a synthetic quaternary ammonium compound, chemically related to atropine.

Ipratropium Bromide Monohydrate     C H BrNO •H O     Mol.Wt. 430.4

Ipratropium bromide is a white crystalline substance, freely soluble in water and lower alcohols. It is a quaternary ammonium compound and thus exists in an ionized state in aqueous solutions. It is relatively insoluble in non-polar media.

Ipratropium Bromide Inhalation Solution is administered by oral inhalation with the aid of a nebulizer. It contains ipratropium bromide, USP 0.02% (anhydrous basis) in a sterile, preservative-free, isotonic saline solution, pH-adjusted to 3.4 (3 to 4) with hydrochloric acid.

Ipratropium bromide is an anticholinergic (parasympatholytic) agent that, based on animal studies, appears to inhibit vagally mediated reflexes by antagonizing the action of acetylcholine, the transmitter agent released from the vagus nerve.

Anticholinergics prevent the increases in intracellular concentration of cyclic guanosine monophosphate (cyclic GMP) that are caused by interaction of acetylcholine with the muscarinic receptor on bronchial smooth muscle.

The bronchodilation following inhalation of ipratropium bromide is primarily a local, site-specific effect, not a systemic one. Much of an administered dose is swallowed but not absorbed, as shown by fecal excretion studies. Following nebulization of a 2 mg dose, a mean 7% of the dose was absorbed into the systemic circulation either from the surface of the lung or from the gastrointestinal tract. The half-life of elimination is about 1.6 hours after intravenous administration. Ipratropium bromide is minimally (0 to 9% in vitro) bound to plasma albumin and a -acid glycoproteins. It is partially metabolized. Autoradiographic studies in rats have shown that ipratropium bromide does not penetrate the blood-brain barrier. Ipratropium bromide has not been studied in patients with hepatic or renal insufficiency. It should be used with caution in those patient populations.

In controlled 12-week studies in patients with bronchospasm associated with chronic obstructive pulmonary disease (chronic bronchitis and emphysema) significant improvements in pulmonary function (FEV increases of 15% or more) occurred within 15 to 30 minutes, reached a peak in 1 to 2 hours, and persisted for periods of 4 to 5 hours in the majority of patients, with about 25% to 38% of the patients demonstrating increases of 15% or more for at least 7 to 8 hours. Continued effectiveness of ipratropium bromide inhalation solution was demonstrated throughout the 12-week period. In addition, significant increases in forced vital capacity (FVC) have been demonstrated. However, ipratropium bromide did not consistently produce significant improvement in subjective symptom scores nor in quality of life scores over the 12-week duration of study.

Additional controlled 12-week studies were conducted to evaluate the safety and effectiveness of ipratropium bromide inhalation solution administered concomitantly with the beta adrenergic bronchodilator solutions metaproterenol and albuterol compared with the administration of each of the beta agonists alone. Combined therapy produced significant additional improvement in FEV and FVC. On combined therapy, the median duration of 15% improvement in FEV was 5 to 7 hours, compared with 3 to 4 hours in patients receiving a beta agonist alone.

Ipratropium Bromide Inhalation Solution administered either alone or with other bronchodilators, especially beta adrenergics, is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema.

Ipratropium bromide is contraindicated in known or suspected cases of hypersensitivity to ipratropium bromide, or to atropine and its derivatives.

The use of ipratropium bromide inhalation solution as a single agent for the relief of bronchospasm in acute COPD exacerbation has not been adequately studied. Drugs with faster onset of action may be preferable as initial therapy in this situation. Combination of ipratropium bromide and beta agonists has not been shown to be more effective than either drug alone in reversing the bronchospasm associated with acute COPD exacerbation.

Immediate hypersensitivity reactions may occur after administration of ipratropium bromide, as demonstrated by rare cases of urticaria, angioedema, rash, bronchospasm and oropharyngeal edema.

Ipratropium bromide should be used with caution in patients with narrow-angle glaucoma, prostatic hypertrophy or bladder-neck obstruction.

Patients should be advised that temporary blurring of vision, precipitation or worsening of narrow-angle glaucoma or eye pain may result if the solution comes into direct contact with the eyes. Use of a nebulizer with mouthpiece rather than face mask may be preferable, to reduce the likelihood of the nebulizer solution reaching the eyes. Patients should be advised that ipratropium bromide inhalation solution can be mixed in the nebulizer with albuterol or metaproterenol if used within one hour. Drug stability and safety of Ipratropium Bromide Inhalation Solution when mixed with other drugs in a nebulizer have not been established. Patients should be reminded that ipratropium bromide inhalation solution should be used consistently as prescribed throughout the course of therapy.

Ipratropium bromide has been shown to be a safe and effective bronchodilator when used in conjunction with beta adrenergic bronchodilators. Ipratropium bromide has also been used with other pulmonary medications, including methylxanthines and corticosteroids, without adverse drug interactions.

Two-year oral carcinogenicity studies in rats and mice have revealed no carcinogenic potential at dietary doses up to 6 mg/kg/day of ipratropium bromide.

Results of various mutagenicity studies (Ames test, mouse dominant lethal test, mouse micronucleus test and chromosome aberration of bone marrow in Chinese hamsters) were negative.

Fertility of male or female rats at oral doses up to 50 mg/kg/day was unaffected by ipratropium bromide administration. At doses above 90 mg/kg increased resorption and decreased conception rates were observed.

Pregnancy Category B Oral reproduction studies performed in mice, rats and rabbits at doses of 10, 100, and 125 mg/kg respectively, and inhalation reproduction studies in rats and rabbits at doses of 1.5 and 1.8 mg/kg (or approximately 38 and 45 times the recommended human daily dose) respectively, have demonstrated no evidence of teratogenic effects as a result of ipratropium bromide. However, no adequate or well-controlled studies have been conducted in pregnant women. Because animal reproduction studies are not always predictive of human response, ipratropium bromide should be used during pregnancy only if clearly needed.

It is not known whether ipratropium bromide is excreted in human milk. Although lipid-insoluble quaternary bases pass into breast milk, it is unlikely that ipratropium bromide would reach the infant to a significant extent, especially when taken by inhalation since ipratropium bromide is not well absorbed systemically after inhalation or oral administration. However, because many drugs are excreted in human milk, caution should be exercised when ipratropium bromide is administered to a nursing woman.

Safety and effectiveness in the pediatric population below the age of 12 have not been established.

Adverse reaction information concerning ipratropium bromide inhalation solution is derived from 12-week active-controlled clinical trials. Additional information is derived from foreign post-marketing experience and the published literature.

All adverse events, regardless of drug relationship, reported by three percent or more patients in the 12-week controlled clinical trials appear in the table below.

Additional adverse reactions reported in less than three percent of the patients treated with ipratropium bromide include tachycardia, palpitations, eye pain, urinary retention, urinary tract infection and urticaria. Cases of precipitation or worsening of narrow-angle glaucoma, mydriasis and acute eye pain have been reported.

Lower respiratory adverse reactions (bronchitis, dyspnea and bronchospasm) were the most common events leading to discontinuation of ipratropium bromide therapy in the 12-week trials. Headache, mouth dryness and aggravation of COPD symptoms are more common when the total daily dose of ipratropium bromide equals or exceeds 2,000 mcg.

Allergic-type reactions such as skin-rash, angioedema of tongue, lips and face, urticaria, laryngospasm and anaphylactic reaction have been reported. Many of the patients had a history of allergies to other drugs and/or foods.

All Adverse Events, from a Double-blind, Parallel, 12-week Study of patients with COPD*
 All adverse events, regardless of drug relationship, reported by three percent or more patients in the 12-week controlled clinical trials.
    Ipratropium   Metaproterenol   Ipratropium/
  Albuterol   Ipratropium/
   (500 mcg t.i.d.)  (15 mg t.i.d.)  (500 mcg t.i.d./
15 mg t.i.d.)
 (2.5 mg t.i.d.)  (500 mcg t.i.d./
2.5 mg t.i.d.)
   n = 219  n = 212  n = 108  n = 205  n = 100
  Body as a Whole-General Disorders          
 Headache  6.4  5.2  6.5  6.3  9.0
 Pain  4.1  3.3  0.9  2.9  5.0
 Influenza-like symptoms  3.7  4.7  6.5  0.5  1.0
 Back Pain  3.2  1.9  1.9  2.4  0.0
 Chest Pain  3.2  4.2  5.6  2.0  1.0
  Cardiovascular Disorders          
 Hypertension/Hypertension Aggravated  0.9  1.9  0.9  1.5  4.0
  Central & Peripheral Nervous System          
 Dizziness  2.3  3.3  1.9  3.9  4.0
 Insomnia  0.9  0.5  4.6  1.0  1.0
 Tremor  0.9  7.1  8.3  1.0  0.0
 Nervousness  0.5  4.7  6.5  1.0  1.0
  Gastrointestinal System Disorders          
 Mouth Dryness  3.2  0.0  1.9  2.0  3.0
 Nausea  4.1  3.8  1.9  2.9  2.0
 Constipation  0.9  0.0  3.7  1.0  1.0
  Musculo -skeletal System Disorders          
 Arthritis  0.9  1.4  0.9  0.5  3.0
  Respiratory System Disorders (Lower)          
 Coughing  4.6  8.0  6.5  5.4  6.0
 Dyspnea  9.6  13.2  16.7  12.7  9.0
 Bronchitis  14.6  24.5  15.7  16.6  20.0
 Bronchospasm  2.3  2.8  4.6  5.4  5.0
 Sputum Increased  1.4  1.4  4.6  3.4  0.0
 Respiratory Disorder  0.0  6.1  6.5  2.0  4.0
  Respiratory System Disorders (Upper)          
 Upper Respiratory Tract Infection  13.2  11.3  9.3  12.2  16.0
 Pharyngitis  3.7  4.2  5.6  2.9  4.0
 Rhinitis  2.3  4.2  1.9  2.4  0.0
 Sinusitus  2.3  2.8  0.9  5.4  4.0

Acute systemic overdosage by inhalation solution is unlikely since ipratropium bromide is not well absorbed after inhalation at up to four-fold the recommended dose, or after oral administration at up to forty-fold the recommended dose. The oral LD of ipratropium bromide ranged between 1001 and 2010 mg/kg in mice; between 1667 and 4000 mg/kg in rats; and between 400 and 1300 mg/kg in dogs.

The usual dosage of ipratropium bromide inhalation solution is 500 mcg (1 Unit-Dose Vial) administered three to four times a day by oral nebulization, with doses 6 to 8 hours apart. Ipratropium bromide inhalation solution unit-dose vials contain 500 mcg ipratropium bromide, USP anhydrous in 2.5 mL normal saline. Ipratropium bromide inhalation solution can be mixed in the nebulizer with albuterol or metaproterenol if used within one hour. Drug stability and safety of Ipratropium Bromide Inhalation Solution when mixed with other drugs in a nebulizer have not been established.

Ipratropium Bromide Inhalation Solution Unit Dose Vial is supplied as a 0.02% clear, colorless solution containing 2.5 mL.

NDC 0591-3798-83, 25 vials in a foil pouch NDC 0591-3798-30, 30 vials in a foil pouch NDC 0591-3798-60, 60 vials, two foil pouches of 30 each

Each vial is made from a low density polyethylene (LDPE) resin.

Vials are supplied in a foil pouch.

Store between 59°F (15°C) and 86°F (30°C).  Protect from light.  Store unused vials in the foil pouch. 

ATTENTION PHARMACIST: Detach “Patient’s Instructions for Use” from Package Insert and dispense with solution.

Rx Only  

Distributed by: Actavis Pharma, Inc. Parsippany, NJ 07054 USA

Manufactured by: The Ritedose Corporation  Columbia, SC 29203

APRIL 2017


Read complete instructions carefully before using.

Note: Use only as directed by your physician.  More frequent administration or higher  doses are not recommended. Ipratropium  Bromide Inhalation Solution can be mixed in  the nebulizer with albuterol or metaproterenol  if used within one hour but not with  other drugs. Drug stability and safety of  Ipratropium Bromide Inhalation Solution  when mixed with other drugs in the nebulizer  have not been established. 

Store between 59°F (15°C) and 86°F (30°C). Protect from light. Store  unused vials in the foil pouch. 

ADDITIONAL INSTRUCTIONS: ____________________________________ ____________________________________ ____________________________________ ____________________________________ ____________________________________ ____________________________________ ____________________________________  

Distributed by: Actavis Pharma, Inc. Parsippany, NJ 07054 USA

Manufactured by: The Ritedose Corporation  Columbia, SC 29203

APRIL 2017

DRUG: Ipratropium Bromide

GENERIC: Ipratropium Bromide



NDC: 70518-1070-0






Active Ingredients


Drugs and Medications [127 Associated Drugs and Medications listed on BioPortfolio]

Ipratropium bromide [unit dose services]

Ipratropium Bromide Inhalation Solution, 0.02% Prescribing Information Rx Only RPIN0020

Ipratropium bromide [cardinal health]

Ipratropium Bromide Inhalation Solution, 0.02% FOR INHALATION USE ONLY – NOT FOR INJECTION

Ipratropium bromide [physicians total care, inc.]


Ipratropium bromide [preferred pharmaceuticals, inc]

Ipratropium Bromide Inhalation Solution, 0.02% FOR INHALATION USE ONLY – NOT FOR INJECTION

Combivent respimat [boehringer ingelheim pharmaceuticals inc.]

These highlights do not include all the information needed to use COMBIVENT RESPIMAT safely and effectively. See full prescribing information for COMBIVENT RESPIMAT. COMBIVENT RESPIMAT (ipratropium br...

Clinical Trials [177 Associated Clinical Trials listed on BioPortfolio]

Duration of Protective Effect From Inhaled Ipratropium Bromide on Methacholine Airway Hyperresponsiveness

Certain lung disease medications can influence diagnostic tests and research investigations. This study will investigate how long ipratropium bromide must be withheld before a methacholin...

Ipratropium Bromide in Peri-Operative COPD

This is a randomized, double-blind, placebo-controlled, parallel-group, multi-centre trial.The trial aims to evaluate efficacy of nebulized ipratropium bromide in Chinese peri-operative pa...

Study to Assess the Effect of Salbutamol and Ipratropium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients

The objectives of this study are to assess the effect of salbutamol in comparison with ipratropium bromide on the geometry of central and peripheral airways and to correlate spirometric in...

Actuation Indicator Trial in Patients With COPD

The primary objective of this study is to evaluate the performance, accuracy, and handling of the actuation indicator in patients with COPD. The actuation indicator is integrated into mou...

Ipratropium Bromide Spray as Treatment for Sialorrhea in Children

Double-blind, clinical trial investigating the effects of ipratropium spray versus placebo spray in children with sialorrhea

PubMed Articles [296 Associated PubMed Articles listed on BioPortfolio]

Clinical features of postinfectious bronchiolitis obliterans in children undergoing long-term nebulization treatment.

Limited data are available in relation to the clinical features of PIBO undergoing prolonged nebulization treatment with budesonide, terbutaline and ipratropium bromide. This retrospective study aimed...

Antifungal effects of BiOBr nanosheets carrying surfactant cetyltrimethylammonium bromide.

BiOBr nanosheets are important photocatalytic nanomaterials. However, their biological effects remain to be explored. In this study, we investigated the antifungal effect of BiOBr nanosheets on Candid...

Impacts of shale gas production wastewater on disinfection byproduct formation: An investigation from a non-bromide perspective.

The rapid rise of shale gas development has triggered environmental and human health concerns due to its impacts on water resources, especially on disinfection byproduct (DBP) formation upon chlorinat...

Coal-fired power plant wet flue gas desulfurization bromide discharges to U.S. watersheds and their contributions to drinking water sources.

Wet flue gas desulfurization (FGD) wastewater discharges from coal-fired power plants may increase bromide concentrations at downstream drinking water intakes, leading to increased formation of toxic ...

Spectral and thermochemical research of the DNA polyplex with chitosan formation process and the influence of anionic and cationic compounds.

In this paper, the results of a spectral and thermochemical study of the DNA polyplex formation with chitosan and the effect of ethidium bromide polyplexes, sodium dodecyl sulfate, n-octyltrimethyl am...

Quick Search


Relevant Topics

Asthma is caused by inflammation of small tubes, called bronchi, which carry air in and out of the lungs. If you have asthma, the bronchi will be inflamed and more sensitive than normal.  When you come into contact with something that irritates your...

Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...

Drugs and Medication Quicklinks

Searches Linking to this Drug Record